ストックスクリーナーアプリを入手
57.94
2.49%
1.41
アフターアワーズ：
57.94
Astrana Health Inc (ASTH) 最新ニュース
Be Wary Of Astrana Health (NASDAQ:ASTH) And Its Returns On Capital - Yahoo Finance
Ascential Shareholding Shifts with Societe Generale’s Move - TipRanks
Magnetar Financial LLC Buys Shares of 20,305 Astera Labs, Inc. (NASDAQ:ALAB) - Defense World
Views of Wall Street’s Leading Experts on Astera Labs Inc. - SETE News
Prospects for datopotamab deruxtecan dented by update - The Pharma Letter
AstraZeneca shares rally 13%, hit record high as firm gets nod for cancer drug Durvalumab - CNBCTV18
Astera Labs, Inc. (NASDAQ:ALAB) Shares Sold by American Century Companies Inc. - Defense World
AstraZeneca Pharma gets nod to sell immunotherapy drug Durvalumab; stock surges - Fortune India
AstraZeneca Pharma shares rally 13%, hit 52-week high after receiving nod for cancer drug Durvalumab - The Economic Times
AstraZeneca Pharma Shares Surge 12% After Approval to Launch Cancer Drug in India - EquityPandit
Pharma stock jumps 12% after it receives nod to import drugs for cancer and tumors - Trade Brains
AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12% - Business Standard
AstraZeneca stock surges over 8% – Check out the reason behind it - Business Upturn
AstraZeneca Pharma India gains on import nod for cancer drug - XM
Astec Lifesciences: Brokerage revises stock's rating post CEO exitDetails - ET Now
AstraZeneca Pharma shares jump 12% to 52-week high on CDSCO permission - Moneycontrol
Aclarion shareholders approve reverse stock split proposal By Investing.com - Investing.com Australia
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug - Investor's Business Daily
This Is What Whales Are Betting On Astera Labs - Benzinga
Indian giant swoops to take over Scottish company - HeraldScotland
Will Astera Labs Inc. (ALAB) meet earnings estimates this quarter? - US Post News
AstraZeneca falls Monday, underperforms market - MarketWatch
Poor trial results dash AstraZeneca’s hopes for $1bn cancer drug - The Times
ProShare Advisors LLC Sells 79,195 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
AstraZeneca's experimental drug disappoints in breast cancer survival trial - Reuters
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial - Investopedia
Summit Trail Advisors LLC Purchases 2,159 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
What is Astrana Health Inc. (ASTH) Stock Return on Shareholders’ Capital? - SETE News
AstraZeneca, Daiichi Sankyo’s ADC Flops in Phase III Breast Cancer on Heels of Lung Cancer Stumble - BioSpace
Ascensos retains Scottish HQ after sale to Firstsource - Daily Business
AstraZeneca breast cancer drug trial fails to extend lives of patients - This is Money
Healthcare stock jumps after it enters in an agreement to set up woman and children hospital By Trade Brains - Investing.com India
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients - Yahoo Finance
Aster enters in an agreement to set up woman and children hospital | Tap to know more | Inshorts - Inshorts
Discovery Capital Management LLC CT Reduces Stake in Astera Labs, Inc. (NASDAQ:ALAB) - Defense World
AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial - Clinical Trials Arena
AstraZeneca’s experimental cancer drug shows no significant improvement in overall survival - WHTC
Aster DM Healthcare to Build Rs 220 Crore Women & Children's Hospital in Hyderabad, Shares Trading Flat - EquityPandit
AstraZeneca falls to five-month low on breast cancer trial results By Proactive Investors - Investing.com UK
AstraZeneca PLC (NASDAQ:AZN) Stock Position Lifted by Massachusetts Financial Services Co. MA - Defense World
Healthcare stock jumps after it enters in an agreement to set up woman and children hospital - Trade Brains
Rhumbline Advisers Takes $1.01 Million Position in Astera Labs, Inc. (NASDAQ:ALAB) - Defense World
AstraZeneca drug fails to extend lives of breast cancer patients - Financial Times
AstraZeneca and Daiichi Suffer New Setback With Mixed Breast Cancer Drug Results - BNN Bloomberg
AstraZeneca's TROPION-BREAST01 Trial: Mixed Results Reported - Devdiscourse
Aster DM arm inks lease agreement with Aparna Constructions & Estates - Business Standard
Astral Resources NL (ASX: AAR) – Trading Halt - Investing News Network
AstraZeneca breast cancer drug trial fails to improve overall survival - Vox Markets
AstraZeneca PLC (NASDAQ:AZN) Stock Position Raised by Sei Investments Co. - Defense World
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Edge Capital Group LLC - Defense World
Aster DM Healthcare Expands into Hyderabad But Stock Seems Overvalued - Investing.com India
Astera Labs, Inc. (NASDAQ:ALAB) Shares Bought by Massachusetts Financial Services Co. MA - Defense World
Victory Capital Management Inc. Invests $815,000 in Astera Labs, Inc. (NASDAQ:ALAB) - Defense World
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Legacy Financial Advisors Inc. - Defense World
Seven Eight Capital LP Invests $994,000 in Astera Labs, Inc. (NASDAQ:ALAB) - Defense World
Astera Labs (NASDAQ:ALAB) Trading 3.8% Higher - Defense World
Tony Bloom’s Hearts investment could be bigger than Souness’ Rangers revolution or McCann transforming Cel... - The Scottish Sun
Astranis Wins Space Force Contract to Add Military Capability to Omega Satellite - Via Satellite
AstraZeneca falls Friday, still outperforms market - MarketWatch
Astranis secures $13.2 million U.S. military contract for satellite upgrades - SpaceNews
Vanguard Personalized Indexing Management LLC Increases Stake in AstraZeneca PLC (NASDAQ:AZN) - Defense World
Rangers and Celtic told to be afraid of news coming out of Hearts right now - Edinburgh News
Can Hearts Tony Bloom tie-up help to bridge gap to Celtic and Rangers? - The National
Aster DM Healthcare quashes merger rumours: Is Blackstone-backed Care Hospitals still in the race? | Company Business News - Mint
Should you buy shares in AstraZeneca? Today’s options explained - The Times
Hearts could receive of £10m investment interest from Brighton owner - Brighton Journal
A History of Outperforming Analyst Forecasts and Beating the Odds: Astera Labs Inc. (ALAB) - SETE News
Aberdeen housebuilder Cala Group sold for £1.35 billion - The Press & Journal
Astrana Health, Inc. (NASDAQ:ASTH) Sees Large Decline in Short Interest - MarketBeat
Astrana Health (NASDAQ:ASTH) Sets New 12-Month High at $54.32 - MarketBeat
Insider Activity Update: Linda Marsh Executes Options Exercise, Resulting In $399K At Astrana Health - Benzinga
Insider Decision: John Vong as Attorney-in-Fact Exercises Options At Astrana Health For $371K - Benzinga
Witnessing An Insider Decision, Mitchell Kitayama Exercises Options Valued At $388K At Astrana Health - Benzinga
Insider Move: Thomas Lam Exercises Options, Realizing $898K At Astrana Health - Benzinga
Astrana Health's (NASDAQ:ASTH) Returns On Capital Not Reflecting Well On The Business - Simply Wall St
Astrana Health Unveils Financial Slides for Conference - TipRanks
Is Astrana Health, Inc.'s (NASDAQ:ASTH) Latest Stock Performance A Reflection Of Its Financial Health? - Yahoo Finance
0.21%
0.20%
大文字化:
|
ボリューム (24 時間):